Wugen
Drug DiscoveryWebsite
Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. The company's technology offers engineered memory natural killer (NK) and CAR-T cell therapies...
Valuation
$245M
Market implied
Share Price
N/A
Total Raised
$323M
Last Round
Later Stage VC (Series C)
Aug 2025
Latest Funding Round
Later Stage VC (Series C)
Aug 27, 2025
$115M
raised
Investors
+13 other investors